»» Searching for " MSHL "
 Related Search Tags:  MSHL CSIQ SLXP PGNX Nasdaq:MSHL Nasdaq:CSIQ Nasdaq:SLXP Nasdaq:PGNX CALP PMIC NASDAQ:CALP Nasdaq:PMIC
Showing Results 1-2 of 2 |  Sort by:     
Page 1 of 1  |  Go to page   
Good Morning, It’s Tuesday Dec 20, 2011, I’m Christina Collins with CRWENewswire Stocks In Action. Marshall Edwards Inc - MSHL - reported that the USPTO has issued a new patent, covering a number of the Company’s isoflavone-based compounds, including lead oncology-drug candidates ME-143 and ME-344, and their pharmaceutical compositions. According to a sales agreement between the companies, TransCanada Corp will acquire from a subsidiary of Canadian Solar Inc - CSIQ - a 86 megawatts AC solar project portfolio for approximately $470 million Canadian dollars. and lastly; Salix Pharmaceuticals Ltd - SLXP - and Progenics Pharmaceuticals Inc - PGNX - reported the successful outcome of the Phase 3 trial to evaluate the efficacy and safety of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. Thank you for joining me and have a great day! For CRWE Newswire, Stocks In Action, I’m Christina Collins
(MSHL, CSIQ, SLXP, PGNX)...
Categories: Videos 
Added: 154 days ago
By: karmastock
Runtime: 1m25s
Views: 47
 | Comments: 0
Not yet rated
Good Thursday Morning, Its September 8th, 2011, I’m Sara Bryant with CRWENewswire Stocks In Action. According to reports, PerkinElmer has agreed to buy Caliper Life Sciences Incorporated - symbol CALP - for $10.50 per share or $600 million. This aquisition will help PerkinElmer broaden its reach in molecular imaging and genomic detection technologies. ACE Limited has entered into a definitive agreement to acquire Penn Millers Holding Corporation - symbol PMIC - for $107 million or $20.50 per share in cash. and finally; Marshall Edwards Incorporated - symbol MSHL - has initiated a Phase I clinical trial of the Company’s lead product candidate ME-143 in patients with refractory solid tumors. According to the company, In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines. Thanks for joining me and have a great day! For CRWE Newswire, Stocks In Action, I’m Sara Bryant
(CALP, PMIC, MSHL)...
Categories: Videos 
Added: 257 days ago
By: karmastock
Runtime: 1m36s
Views: 77
 | Comments: 0
Not yet rated
Page 1 of 1  |  Go to page   
About Us   |   Terms of Use   |   Privacy Policy   |   Copyright Notes   |   Contact Us   |   Help   |      |   Back to the top of this page
Copyright © 2006-2007 bongoTYube. All rights reserved.    | Page created in 0.0455 seconds.